Since GBM is a type of cancers associated with aberrant activation of NF-κB pathway [1,15], investigating the micoRNA targets of HOXD-AS2 and its potential role in pathway could provide novel insights for therapeutic intervention. The gene discussed is NFKB1; the disease is cancer.